Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Artificial Intelligence | 2 | 2023 | 70 | 1.030 |
Why?
|
| Hospital Mortality | 4 | 2020 | 187 | 0.970 |
Why?
|
| Drug Combinations | 1 | 2024 | 98 | 0.920 |
Why?
|
| Antimalarials | 1 | 2024 | 55 | 0.900 |
Why?
|
| Drug Synergism | 1 | 2024 | 177 | 0.900 |
Why?
|
| Plasmodium falciparum | 1 | 2024 | 135 | 0.840 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 169 | 0.750 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2020 | 13 | 0.730 |
Why?
|
| Mitral Valve | 1 | 2020 | 19 | 0.730 |
Why?
|
| Computational Biology | 4 | 2023 | 293 | 0.690 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 47 | 0.670 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2014 | 67 | 0.480 |
Why?
|
| Biomedical Research | 3 | 2023 | 400 | 0.470 |
Why?
|
| Saccharomyces cerevisiae Proteins | 3 | 2021 | 118 | 0.450 |
Why?
|
| Saccharomyces cerevisiae | 3 | 2021 | 206 | 0.430 |
Why?
|
| Humans | 18 | 2024 | 37093 | 0.330 |
Why?
|
| Risk Assessment | 3 | 2019 | 753 | 0.310 |
Why?
|
| Treatment Outcome | 3 | 2019 | 1369 | 0.290 |
Why?
|
| Proteomics | 2 | 2024 | 325 | 0.250 |
Why?
|
| United States | 5 | 2022 | 4223 | 0.240 |
Why?
|
| Cannabinoids | 1 | 2024 | 56 | 0.230 |
Why?
|
| Bayes Theorem | 2 | 2021 | 94 | 0.230 |
Why?
|
| Reference Values | 1 | 2023 | 212 | 0.220 |
Why?
|
| Drug Therapy, Combination | 1 | 2024 | 227 | 0.220 |
Why?
|
| Malaria, Falciparum | 1 | 2024 | 90 | 0.210 |
Why?
|
| Puerto Rico | 2 | 2024 | 1378 | 0.210 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 610 | 0.200 |
Why?
|
| SELEX Aptamer Technique | 1 | 2021 | 5 | 0.200 |
Why?
|
| Cisplatin | 1 | 2022 | 72 | 0.200 |
Why?
|
| Databases, Factual | 2 | 2019 | 291 | 0.200 |
Why?
|
| Aptamers, Nucleotide | 1 | 2021 | 31 | 0.200 |
Why?
|
| Receptors, Cell Surface | 1 | 2021 | 144 | 0.180 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2021 | 48 | 0.180 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 146 | 0.180 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2021 | 103 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2022 | 222 | 0.180 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2019 | 13 | 0.170 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2023 | 767 | 0.170 |
Why?
|
| Geography | 1 | 2019 | 96 | 0.170 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 23 | 0.170 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 2379 | 0.170 |
Why?
|
| ras Proteins | 1 | 2019 | 51 | 0.160 |
Why?
|
| Burns | 1 | 2018 | 7 | 0.160 |
Why?
|
| Software | 2 | 2023 | 217 | 0.160 |
Why?
|
| Platelet Aggregation | 1 | 2018 | 19 | 0.160 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 400 | 0.160 |
Why?
|
| Ovarian Neoplasms | 1 | 2022 | 312 | 0.160 |
Why?
|
| HIV-1 | 1 | 2024 | 706 | 0.160 |
Why?
|
| Receptors, Immunologic | 1 | 2018 | 61 | 0.150 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2019 | 187 | 0.150 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2024 | 182 | 0.150 |
Why?
|
| Wound Healing | 1 | 2018 | 70 | 0.150 |
Why?
|
| Antifungal Agents | 1 | 2019 | 148 | 0.150 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 664 | 0.140 |
Why?
|
| Skin | 1 | 2018 | 174 | 0.140 |
Why?
|
| Primary Health Care | 1 | 2019 | 294 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 290 | 0.140 |
Why?
|
| Aged | 4 | 2024 | 6741 | 0.140 |
Why?
|
| Algorithms | 2 | 2021 | 465 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2022 | 807 | 0.140 |
Why?
|
| Female | 8 | 2024 | 20969 | 0.140 |
Why?
|
| Membrane Proteins | 1 | 2019 | 517 | 0.130 |
Why?
|
| Antineoplastic Agents | 1 | 2022 | 803 | 0.120 |
Why?
|
| Risk Factors | 2 | 2019 | 3562 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 494 | 0.120 |
Why?
|
| Nucleotides | 2 | 2024 | 36 | 0.120 |
Why?
|
| Placenta | 2 | 2022 | 97 | 0.100 |
Why?
|
| Male | 5 | 2024 | 20025 | 0.090 |
Why?
|
| HIV Infections | 1 | 2024 | 2303 | 0.090 |
Why?
|
| Minority Groups | 2 | 2022 | 596 | 0.080 |
Why?
|
| Pregnancy | 2 | 2022 | 1549 | 0.070 |
Why?
|
| Exocytosis | 1 | 2024 | 47 | 0.060 |
Why?
|
| Blood Proteins | 1 | 2024 | 66 | 0.060 |
Why?
|
| Mutagenesis | 1 | 2024 | 89 | 0.060 |
Why?
|
| Lysosomes | 1 | 2024 | 91 | 0.060 |
Why?
|
| Writing | 1 | 2023 | 37 | 0.060 |
Why?
|
| Open Reading Frames | 1 | 2023 | 77 | 0.060 |
Why?
|
| Cystatin B | 1 | 2022 | 7 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2022 | 88 | 0.050 |
Why?
|
| Minority Health | 1 | 2022 | 88 | 0.050 |
Why?
|
| Faculty | 1 | 2022 | 94 | 0.050 |
Why?
|
| Language | 1 | 2023 | 157 | 0.050 |
Why?
|
| RNA Splicing | 1 | 2022 | 40 | 0.050 |
Why?
|
| Decision Trees | 1 | 2021 | 19 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 333 | 0.050 |
Why?
|
| Natural Language Processing | 1 | 2021 | 12 | 0.050 |
Why?
|
| Fibrinogen | 1 | 2021 | 23 | 0.050 |
Why?
|
| Young Adult | 2 | 2024 | 4268 | 0.050 |
Why?
|
| Gene Library | 1 | 2021 | 57 | 0.050 |
Why?
|
| Research Personnel | 1 | 2022 | 155 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 1 | 2022 | 173 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2024 | 339 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2022 | 275 | 0.050 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2021 | 67 | 0.050 |
Why?
|
| Protein Interaction Mapping | 1 | 2021 | 61 | 0.050 |
Why?
|
| Metabolomics | 1 | 2021 | 81 | 0.050 |
Why?
|
| Extracellular Matrix | 1 | 2021 | 115 | 0.050 |
Why?
|
| Macrophages | 1 | 2024 | 439 | 0.050 |
Why?
|
| Cytokines | 1 | 2024 | 602 | 0.050 |
Why?
|
| Ligands | 1 | 2021 | 349 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2021 | 142 | 0.040 |
Why?
|
| Proteome | 1 | 2021 | 144 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2022 | 893 | 0.040 |
Why?
|
| Prognosis | 1 | 2022 | 739 | 0.040 |
Why?
|
| Hospital Costs | 1 | 2019 | 24 | 0.040 |
Why?
|
| Mutation | 1 | 2024 | 1095 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2019 | 90 | 0.040 |
Why?
|
| Haplotypes | 1 | 2019 | 182 | 0.040 |
Why?
|
| Cytoplasmic Granules | 1 | 2018 | 8 | 0.040 |
Why?
|
| Logistic Models | 1 | 2021 | 923 | 0.040 |
Why?
|
| Inpatients | 1 | 2019 | 74 | 0.040 |
Why?
|
| Clone Cells | 1 | 2018 | 47 | 0.040 |
Why?
|
| Administration, Cutaneous | 1 | 2018 | 43 | 0.040 |
Why?
|
| Protein Binding | 1 | 2021 | 972 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2019 | 201 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2024 | 938 | 0.040 |
Why?
|
| Length of Stay | 1 | 2019 | 185 | 0.040 |
Why?
|
| Immunization | 1 | 2018 | 92 | 0.040 |
Why?
|
| Immunoprecipitation | 1 | 2018 | 131 | 0.040 |
Why?
|
| Inflammation | 1 | 2022 | 618 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2019 | 210 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2022 | 681 | 0.040 |
Why?
|
| Rabbits | 1 | 2018 | 283 | 0.040 |
Why?
|
| Middle Aged | 2 | 2024 | 10129 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2018 | 77 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 626 | 0.040 |
Why?
|
| Adult | 2 | 2024 | 11712 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2022 | 1198 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2018 | 859 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2018 | 1180 | 0.030 |
Why?
|
| Peptides | 1 | 2018 | 320 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2019 | 808 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2022 | 2231 | 0.030 |
Why?
|
| Gene Expression | 1 | 2018 | 674 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 2721 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 1455 | 0.030 |
Why?
|
| Time Factors | 1 | 2019 | 1742 | 0.030 |
Why?
|
| Child | 1 | 2019 | 3131 | 0.020 |
Why?
|
| Adolescent | 1 | 2019 | 5363 | 0.020 |
Why?
|
| Mice | 1 | 2018 | 5913 | 0.020 |
Why?
|
| Animals | 1 | 2018 | 15081 | 0.010 |
Why?
|